

Corporate Information

BOARD OF DIRECTORS

John C. Martin, PhD
Executive Chairman,
Gilead Sciences

John F. Cogan, PhD
Lead Independent Director,
Gilead Sciences

Kelly A. Kramer
Executive Vice President and Chief
Financial Officer, Cisco Systems, Inc.

Kevin E. Lofton, FACHE
Chief Executive Officer,
Catholic Health Initiatives

John W. Madigan
Retired Chairman and Chief Executive
Officer, Tribune Company

John F. Milligan, PhD
President and Chief Executive Officer,
Gilead Sciences

Nicholas G. Moore
Retired Global Chairman,
PricewaterhouseCoopers

Richard J. Whitley, MD
Distinguished Professor,
Loeb Scholar Chair in Pediatrics,
Professor of Pediatrics, Microbiology,
Medicine, and Neurosurgery,
University of Alabama at Birmingham

Gayle Edlund Wilson
Chairman Emeritus of COSMOS,
The California State Summer School
for Math and Science

Per Wold-Olsen
Retired President, Human Health
Intercontinental Division,
Merck & Co., Inc.

DIRECTOR EMERITUS, GILEAD SCIENCES BOARD OF DIRECTORS

George P. Shultz, PhD
Distinguished Fellow, Hoover
Institution, Stanford University

SENIOR MANAGEMENT TEAM

John F. Milligan, PhD
President and Chief Executive Officer

John C. Martin, PhD
Executive Chairman

Gregg H. Alton
Executive Vice President,
Corporate and Medical Affairs

Norbert W. Bischofberger, PhD
Executive Vice President,
Research and Development and
Chief Scientific Officer

Andrew Cheng, MD, PhD
Executive Vice President, Clinical
Research and Development Operations

William A. Lee, PhD
Executive Vice President, Research

John McHutchison, MD
Executive Vice President,
Clinical Research

Jim Meyers
Executive Vice President,
Worldwide Commercial Operations

Brett A. Pletcher
Executive Vice President, General
Counsel and Chief Compliance Officer

Martin B. Silverstein, MD
Executive Vice President, Strategy

Robin L. Washington
Executive Vice President and
Chief Financial Officer

Katie L. Watson
Executive Vice President,
Human Resources

Taiyin Yang, PhD
Executive Vice President,
Pharmaceutical Development
and Manufacturing

Kevin Young CBE
Chief Operating Officer

SCIENTIFIC ADVISORY BOARD

Joel R. Huff, PhD (Chairperson)
Retired, Vice President of Medicinal
Chemistry, Merck Research
Laboratories

Nezam H. Afdhal, MD
Chief of Hepatology and Director of
the Liver Center, Beth Israel Deaconess
Medical Center, Professor of Medicine,
Harvard Medical School

Kenneth C. Anderson, MD
Kraft Family Professor of Medicine,
Harvard Medical School, Director,
LeBow Institute for Myeloma
Therapeutics, Director, Jerome Lipper
Multiple Myeloma Center, Dana-
Farber Cancer Institute

Paul Berg, PhD
Cahill Professor of Biochemistry,
Emeritus, Stanford University School
of Medicine

Francis V. Chisari, MD
Emeritus Professor of Virology,
Department of Immunology
and Microbial Science,
The Scripps Research Institute

Brian J. Druker, MD
Director, Knight Cancer Institute
Associate Dean for Oncology, School of
Medicine, JELD-WEN Chair of
Leukemia Research, Oregon Health &
Science University, Investigator,
Howard Hughes Medical Institute

Mark C. Genovese, MD
James W. Raitt Professor of Medicine,
Director of the Rheumatology Clinic,
Division of Immunology and
Rheumatology, Stanford University
Medical Center

Robert (Bob) A. Harrington, MD
Arthur L. Bloomfield Professor of
Medicine, Chair, Department of
Medicine, Stanford University School
of Medicine

Paul Klotman, MD
President, Chief Executive Officer, and
Executive Dean,
John E. and Clara B. Whitmore
Professor, Baylor College of Medicine

Malcolm MacCoss, PhD, FRSC
Founder and Member,
Bohicket Pharma Consulting LLC,
Visiting Professor of Chemistry for
Medicine, University of Oxford, UK

John W. Mellors, MD
Professor of Medicine,
Chief, Division of Infectious Diseases,
University of Pittsburgh School of
Medicine

Eugene R. Schiff, MD
Leonard Miller Professor of Medicine,
Dr. Nasser Ibrahim Al-Rashid Chair in
the Schiff Center for Liver Diseases,
Director, Schiff Center for Liver
Diseases, Director, Hepatology Research
Laboratory, University of Miami Miller
School of Medicine

Robert T. Schooley, MD
Professor of Medicine and Head,
Division of Infectious Diseases,
Vice Chair of Department of Medicine,
University of California, San Diego

Eric J. Topol, MD
Director, Scripps Translational Science
Institute, Chief Academic Officer,
Scripps Health, Professor of Genomics,
The Scripps Research Institute

CORPORATE SECRETARY

Brett A. Pletcher
General Counsel / Corporate Secretary

**INDEPENDENT REGISTERED
PUBLIC ACCOUNTANTS**
Ernst & Young LLP
Palo Alto, California

CORPORATE HEADQUARTERS

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 USA
(800) 445-3235 or
(650) 574-3000
www.gilead.com

STOCKHOLDER INQUIRIES

Inquiries from our stockholders and
potential investors regarding our company
are always welcome and will receive a
prompt response. Please direct your
requests for information to:

Investor Relations
Gilead Sciences, Inc.
333 Lakeside Drive
Foster City, CA 94404 USA
(800) 445-3235 or
(650) 574-3000

Information regarding Gilead also
is available at www.gilead.com.

STOCK LISTING

Gilead common stock is traded
on the Nasdaq Global Select Stock
Market, under the symbol GILD.

ANNUAL MEETING

The annual meeting of stockholders
will be held at **10:00 a.m. on
Wednesday, May 10, 2017**, at the
Westin San Francisco Airport Hotel.

TRANSFER AGENT AND REGISTRAR

Communications concerning stock transfer
requirements, lost certificates and changes
of address should be directed to the
Transfer Agent:

Computershare
P.O. BOX 30170
College Station, TX 77842-3170
(800) 710-0940
www.computershare.com/investor

EQUAL OPPORTUNITY EMPLOYER

Gilead Sciences is proud to be an equal
opportunity employer and extends
employment to men and women
from culturally diverse backgrounds.
Our environment respects individual
differences and recognizes each employee
as an integral member of our company.
Our workforce reflects these values and
celebrates the individuals who make up
our growing team.